The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis.
Ki-67
carcinoid
neuroendocrine
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
24 08 2019
24 08 2019
Historique:
entrez:
26
8
2019
pubmed:
26
8
2019
medline:
15
9
2020
Statut:
epublish
Résumé
The omission of the immunohistochemical proliferation marker Ki-67 labelling index (henceforth, simply Ki-67) from the 2015 WHO classification system of pulmonary neuroendocrine tumours (Lung-NETs) as a prognostic and grading criterion remains controversial. This systematic review along with meta-analysis will be conducted to assess the prognostic/grading utility of Ki-67 in Lung-NETs. This systematic review will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. A systematic search of MEDLINE Ovid, Embase, Scopus and the Cochrane Library will be performed from the inception of each database to 28 February 2019 for studies investigating any role of Ki-67 in Lung-NETs. Only full papers published in English detailing survival outcomes and HRs according to Ki-67 will be included. The primary endpoint will be establishing whether Ki-67 is a reliable marker in determining prognosis and thus assessing grade of Lung-NETs patients. Ethical approval will not be required as this is an academic review of published literature. Findings will be disseminated through the preparation of a manuscript for publication in a peer-reviewed journal as well as presentation at national and international conferences. CRD42018093389.
Identifiants
pubmed: 31446421
pii: bmjopen-2019-031531
doi: 10.1136/bmjopen-2019-031531
pmc: PMC6720315
doi:
Substances chimiques
Biomarkers, Tumor
0
Ki-67 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e031531Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Cancer. 2003 Feb 15;97(4):934-59
pubmed: 12569593
Br J Cancer. 2005 Aug 22;93(4):387-91
pubmed: 16106245
Br J Cancer. 2007 May 21;96(10):1504-13
pubmed: 17453008
J Clin Oncol. 2007 Nov 20;25(33):5287-312
pubmed: 17954709
Breast. 2008 Aug;17(4):323-34
pubmed: 18455396
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
J Clin Oncol. 2009 Jul 1;27(19):3177-84
pubmed: 19470936
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Am J Surg Pathol. 2010 Mar;34(3):300-13
pubmed: 20118772
Cancer. 2011 Aug 1;117(15):3332-41
pubmed: 21246527
J Clin Pathol. 2013 Aug;66(8):700-4
pubmed: 23703851
Endocr Relat Cancer. 2013 Dec 16;21(1):1-16
pubmed: 24344249
J Thorac Oncol. 2014 Mar;9(3):273-84
pubmed: 24518085
Mod Pathol. 2015 May;28(5):686-94
pubmed: 25412850
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
J Clin Pathol. 2016 Jul;69(7):612-8
pubmed: 26680267
Nature. 2016 Jun 29;535(7611):308-12
pubmed: 27362226
Histol Histopathol. 2017 Mar;32(3):223-241
pubmed: 27628949
Virchows Arch. 2017 Feb;470(2):153-164
pubmed: 28054150
Virchows Arch. 2018 Mar;472(3):341-349
pubmed: 29134440
Mod Pathol. 2018 Oct;31(10):1523-1531
pubmed: 29802361
Endocrinol Metab Clin North Am. 2018 Sep;47(3):463-470
pubmed: 30098710
Clin Chim Acta. 2019 Apr;491:39-45
pubmed: 30653951
Int J Cancer. 1983 Jan 15;31(1):13-20
pubmed: 6339421
Cancer. 1995 Jan 1;75(1 Suppl):191-202
pubmed: 8000996
Hum Pathol. 1996 Nov;27(11):1124-34
pubmed: 8912819